Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection: Draft Guidance for Industry

Biocon Biologics Inc. supports the draft guidance but requests specific clarifications and revisions to reduce administrative burdens and protect legal privileges. They advocate for clearer definitions regarding response preparers, the use of consultants, and the development of a centralized submission portal for large files.

The Association for Accessible Medicines (AAM) supports the Draft Guidance for clarifying FDA expectations for responding to Form 483 observations but requests specific modifications to protect attorney-client privilege and reduce unnecessary administrative burdens. They argue for clearer definitions regarding "response preparers," the removal of mandatory disclosure of outside counsel, and the establishment of more transparent communication channels for scientific disagreements.

Bharathi Kodali provides several specific technical proposals to improve the draft guidance, including establishing distinct standards for repeat observations, clarifying attorney-client privilege, and creating a tiered effectiveness check framework. The commenter argues that these changes would improve the quality of responses from manufacturers, account for the logistical realities of foreign establishments, and promote proactive quality management.